C1498

C1498是可作為急性骨髓性白血病模型的小鼠白血病細胞系^[1]，具有很少的細胞表面造血標記物^[2]，並且是通過分泌可溶性細胞因子抑制着正常小鼠造血的功能^[3]。C1498細胞在培養基中表達低水平的細胞程式死亡-配體1 (PD-L1) ^[4]，然而在生物體內則顯著上調PD-L1的表達^[5]。

歷史

1941年，科學家從10個月大且患有白血病的雌性 C57BL/6小鼠中分離出C1498細胞，並且將其以靜脈注射的方式注射到同系小鼠的體內，導致其患有急性白血病。C1498細胞自始成為急性白血病的模型，有多份文獻記載着通過靜脈、皮下或腹膜的途徑，將高度增殖的C1498細胞，注射入易受感染的小鼠後，血液、脾臟和淋巴結等造血器官，以及卵巢和腎臟等非造血器官的情況^[6]^[7]。較早前的研究認為小鼠模型誘導粒細胞性單核細胞性白血病^[6]^[8]或骨髓單核細胞性白血病^[2]。

在2002年，有研究將這種癌症正式描述為鼠類NKT細胞白血病^[1]，惟因許多研究都是在1950年代-1970年代進行而缺乏有關細胞及白血病疾病的詳細及更新的公開資料，關於C1498細胞的性質及其在小鼠中誘發的相關白血病，在不同文獻具有差異性^[9]。

在2016年，有研究指出注射C1498細胞至小鼠體內後，觀察到的許多白血病特徵與人類急性髓單核細胞白血病相同^[10]，入侵的白血病細胞導致成熟的和未成熟的祖細胞及前體骨髓造血細胞減，並且發現C1498細胞以較高的比率存在於外周血^[9]。

參考資料

^ ^1.0 ^1.1 LaBelle, JL; Truitt, RL. Characterization of a murine NKT cell tumor previously described as an acute myelogenous leukemia.. Leukemia & lymphoma. 2002-08, 43 (8): 1637–44 [2019-12-14]. PMID 12400607. doi:10.1080/1042819021000002974.
^ ^2.0 ^2.1 Boyer, MW; Orchard, PJ; Gorden, KB; Anderson, PM; Mclvor, RS; Blazar, BR. Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia.. Blood. 1995-05-01, 85 (9): 2498–506 [2019-12-14]. PMID 7727779.
^ Quesenberry, PJ; Rappeport, JM; Fountebouni, A; Sullivan, R; Zuckerman, K; Ryan, M. Inhibition of normal murine hematopoiesis by leukemic cells.. The New England journal of medicine. 1978-07-13, 299 (2): 71–5 [2019-12-14]. PMID 351395. doi:10.1056/NEJM197807132990204.
^ Zhang, L; Gajewski, TF; Kline, J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.. Blood. 2009-08-20, 114 (8): 1545–52 [2019-12-14]. PMID 19417208. doi:10.1182/blood-2009-03-206672.
^ DAVERN; BASUS; GARCIAMANEROG等. Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML). Blood. 2016, 128 (22): 2900–05. doi:10.1158/1538-7445.AM2016-3205.
^ ^6.0 ^6.1 GOLDIE, H; BUTLER, CH; ANDERSON, MM; MAXWELL, MC; HAHN, PF. Growth characteristics of free C1498 granulocytic leukemia tumor cells in the peritoneal fluid and the blood of C57 mice.. Cancer research. 1953-02, 13 (2): 125–9 [2019-12-14]. PMID 13042796.
^ TANAKA, KK; ROBERTS, E. BIOLOGICAL STUDIES OF E.L.4 LYMPHOMA AND C-1498 LEUKEMIA IN SUSCEPTIBLE (C57BL) AND RESISTANT (B10.D2) MICE.. Cancer research. 1964-11, 24: 1785–97 [2019-12-14]. PMID 14230926.
^ Graham JD; McMahon Welch C; Patchen ML. Studies of an implanted murine myelogenous leukemia C1498. The Ohio Journal of Science. 1975, 75 (4): 202–208 [2019-12-14].
^ ^9.0 ^9.1 Mopin, A; Driss, V; Brinster, C. A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model.. Journal of visualized experiments : JoVE. 2016-10-14, (116) [2019-12-14]. PMID 27768040. doi:10.3791/54270.
^ Xu, Y; McKenna, RW; Wilson, KS; Karandikar, NJ; Schultz, RA; Kroft, SH. Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation.. Leukemia. 2006-07, 20 (7): 1321–4 [2019-12-14]. PMID 16642046. doi:10.1038/sj.leu.2404242.

外部連結

Cellosaurus entry for C1498（頁面存檔備份，存於互聯網檔案館）

[b-1] 1.0 ^1.1 LaBelle, JL; Truitt, RL. Characterization of a murine NKT cell tumor previously described as an acute myelogenous leukemia.. Leukemia & lymphoma. 2002-08, 43 (8): 1637–44 [2019-12-14]. PMID 12400607. doi:10.1080/1042819021000002974.

[d-2] 2.0 ^2.1 Boyer, MW; Orchard, PJ; Gorden, KB; Anderson, PM; Mclvor, RS; Blazar, BR. Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia.. Blood. 1995-05-01, 85 (9): 2498–506 [2019-12-14]. PMID 7727779.

[3] Quesenberry, PJ; Rappeport, JM; Fountebouni, A; Sullivan, R; Zuckerman, K; Ryan, M. Inhibition of normal murine hematopoiesis by leukemic cells.. The New England journal of medicine. 1978-07-13, 299 (2): 71–5 [2019-12-14]. PMID 351395. doi:10.1056/NEJM197807132990204.

[4] Zhang, L; Gajewski, TF; Kline, J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.. Blood. 2009-08-20, 114 (8): 1545–52 [2019-12-14]. PMID 19417208. doi:10.1182/blood-2009-03-206672.

[5] DAVERN; BASUS; GARCIAMANEROG等. Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML). Blood. 2016, 128 (22): 2900–05. doi:10.1158/1538-7445.AM2016-3205.

[a-6] 6.0 ^6.1 GOLDIE, H; BUTLER, CH; ANDERSON, MM; MAXWELL, MC; HAHN, PF. Growth characteristics of free C1498 granulocytic leukemia tumor cells in the peritoneal fluid and the blood of C57 mice.. Cancer research. 1953-02, 13 (2): 125–9 [2019-12-14]. PMID 13042796.

[7] TANAKA, KK; ROBERTS, E. BIOLOGICAL STUDIES OF E.L.4 LYMPHOMA AND C-1498 LEUKEMIA IN SUSCEPTIBLE (C57BL) AND RESISTANT (B10.D2) MICE.. Cancer research. 1964-11, 24: 1785–97 [2019-12-14]. PMID 14230926.

[8] Graham JD; McMahon Welch C; Patchen ML. Studies of an implanted murine myelogenous leukemia C1498. The Ohio Journal of Science. 1975, 75 (4): 202–208 [2019-12-14].

[c-9] 9.0 ^9.1 Mopin, A; Driss, V; Brinster, C. A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model.. Journal of visualized experiments : JoVE. 2016-10-14, (116) [2019-12-14]. PMID 27768040. doi:10.3791/54270.

[10] Xu, Y; McKenna, RW; Wilson, KS; Karandikar, NJ; Schultz, RA; Kroft, SH. Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation.. Leukemia. 2006-07, 20 (7): 1321–4 [2019-12-14]. PMID 16642046. doi:10.1038/sj.leu.2404242.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]